Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT - CHINA'S FIRST ANTI-GFRAL MONOCLONAL ANTIBODY JMT203 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

VOLUNTARY ANNOUNCEMENT - CHINA'S FIRST ANTI-GFRAL MONOCLONAL ANTIBODY JMT203 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

June 27, 2023

3_00(1).jpg



3_01(1).jpg




Previous: CSPC Attending Beijing-Tianjin-Hebei Pharmaceutical Innovation and Development Conference

Next: VOLUNTARY ANNOUNCEMENT - TEDIZOLID PHOSPHATE FOR INJECTION OBTAINS DRUG REGISTRATION APPROVAL

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat